ClinicalTrials.gg
CompletedNCT00552097ENHANCEUpdated Aug 15, 2024

Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)

A Phase 3 interventional study of ezetimibe (plus simvastatin) and placebo (plus simvastatin) in Atherosclerosis, Hypercholesterolemia and Hyperlipoproteinemia Type II, sponsored by Organon and Co. Completed. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Organon and Co · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 5 years 4 months after the study started (first participant enrolled Jun 2002, registered Oct 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies testing ezetimibe in Atherosclerosis — 2 open to participants now, 2 under way, none of them phase 3. Ezetimibe · Atherosclerosis.

Enrollment
3rd of 22
720 · median 121
Started
2002
the only one that year
Phase 3
6 of 22
none open now
Registered
7th of 22
by date
Lead sponsor
11 of 22
Organon and Co

Among the 22 studies testing ezetimibe in Atherosclerosis, this one is the 3rd largest by enrollment, is the only one that started in 2002, is one of 6 in phase 3, and was the 7th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

2 of the 22 studies testing ezetimibe in Atherosclerosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ezetimibe in Atherosclerosis, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether ezetimibe plus simvastatin will be more effective than simvastatin alone in preventing progression of atherosclerosis of the inner layer of the carotid artery.

03

Conditions studied

  • Atherosclerosis
  • Hypercholesterolemia
  • Hyperlipoproteinemia Type II
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Genotype-confirmed heterozygous familial hypercholesterolemia with written documentation of the genetic diagnosis at the time of screening and LDL-C >=210 mg/dL (5.43 mmol/L), or clinical diagnosis of heterozygous familial hypercholesterolemia, defined as LDL-C >=210 mg/dL (5.43 mmol/L) and at least one of the following:

    • tendinous xanthoma
    • child \<18 years of age with hypercholesterolemia (LDL-C >159 mg/dL (4.11 mmol/L)
    • has a sibling with hypercholesterolemia (LDL-C >190 mg/dL [4.91 mmol/L]) and tendinous xanthoma
    • family history with an LDL-C value distribution pattern compatible with dominant autosomal transmission and at least one relative presenting fasting total cholesterol values >348 mg/dL (9.0 mmol/L) after exclusion of secondary causes of dyslipidemia
  • LDL-C >=210 mg/dL (5.43 mmol/L) 1 week before randomization
  • plasma triglyceride level \<=400 mg/dL (4.52 mmol/L)

Exclusion criteria

Exclusion Criteria:

  • pregnancy or any other situation, condition, or illness that, in the opinion of the investigator, may interfere with optimal participation in the study
  • presence of an apolipoprotein B gene mutation with confirmed absence of an LDL receptor mutation in either allele
  • undergoing LDL-apheresis or plasma apheresis
  • unsuitable plaque or artery morphology
  • use of certain drugs, foods, or other agents known to alter cholesterol levels or to cause pharmacokinetic interactions with either ezetimibe or simvastatin
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
720 participants (actual)

Study arms

  • Experimental
    EZ/Simva

    Drug: ezetimibe (plus simvastatin)

  • Placebo comparator
    Placebo/Simva

    Drug: placebo (plus simvastatin)

Interventions

  • Drugezetimibe (plus simvastatin)

    Drug page: Ezetimibe

    oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months

    Also known as: ZETIA, VYTORIN, SCH 58235, SCH 465981

  • Drugplacebo (plus simvastatin)

    tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months

06

What researchers measure

Primary outcomes

  1. Change in ultrasound-determined average carotid artery intima-media thickness (IMT) on a per subject basis between baseline and endpoint.

    Time frame: 24 months

Secondary outcomes

  1. Proportion of subjects with a reduction in ultrasound-determined average carotid artery IMT between baseline and endpoint.

    Time frame: 24 months

  2. Change in ultrasound-determined maximum carotid artery IMT on a per subject basis between baseline and endpoint.

    Time frame: 24 months

  3. Proportion of subjects developing new carotid artery plaques between baseline and endpoint.

    Time frame: 24 months

  4. Change in ultrasound-determined average carotid artery plus average common femoral artery IMT on a per subject basis between baseline and endpoint.

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kastelein JJ, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J. 2005 Feb;149(2):234-9. doi: 10.1016/j.ahj.2004.06.024. PubMed 15846260 ↗
  • Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008 Apr 3;358(14):1431-43. doi: 10.1056/NEJMoa0800742. Epub 2008 Mar 30. Erratum In: N Engl J Med. 2008 May 1;358(18):1977. PubMed 18376000 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2002 to primary completion in Apr 2006, 46 months.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 46 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2007
First posted
Nov 1, 2007
StartActual
Jun 1, 2002
Primary completionActual
Apr 25, 2006
CompletionActual
Apr 25, 2006
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00552097
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Nov 1, 2007
Start date
Jun 1, 2002
Primary completion
Apr 25, 2006
Completion
Apr 25, 2006
Last update
Aug 15, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion